Search results
Brokerage maintains buy on AstraZeneca shares, sees growth potential By Investing.com
Investing.com· 7 hours agoOn Friday, TD Cowen affirmed its positive stance on AstraZeneca (NASDAQ:AZN), maintaining a Buy...
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 2 days agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 3 days agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 5 days agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
CNBC· 8 hours agoPatients with musculoskeletal conditions who like to stay in their pajamas received some welcome...
AstraZeneca completes Fusion Pharmaceuticals acquisition
Pharmaceutical Technology via Yahoo Finance· 3 days agoAstraZeneca has announced the conclusion of its acquisition of clinical-stage biopharmaceutical...
AstraZeneca invests in Nucleus RadioPharmaceuticals - Minneapolis / St. Paul Business Journal
The Business Journals· 1 day agoAfter completing a $56 million Series A funding round in 2023, Nucleus RadioPharma scored an...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 9 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 2 days agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 7 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...